Albina Nesterova

2.3k total citations · 1 hit paper
24 papers, 1.9k citations indexed

About

Albina Nesterova is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Albina Nesterova has authored 24 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Molecular Biology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Albina Nesterova's work include Monoclonal and Polyclonal Antibodies Research (4 papers), Trace Elements in Health (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Albina Nesterova is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (4 papers), Trace Elements in Health (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Albina Nesterova collaborates with scholars based in United States, Japan and Germany. Albina Nesterova's co-authors include Jane E.B. Reusch, Linda M. Boxer, Subbiah Pugazhenthi, Kim A. Heidenreich, Lynn E. Heasley, Carol L. Sable, P.A. Watson, Dwight J. Klemm, Leia M. Smith and Martha E. Anderson and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Albina Nesterova

24 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Akt/Protein Kinase B Up-regulates Bcl-2 Expression through cAMP-response Element-binding Protein

2000 697 citations Subbiah Pugazhenthi, Albina Nesterova et al. Journal of Biological Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Albina Nesterova United States	14	995	603	278	211	207	24	1.9k
Nuray Erin Türkiye	25	1.0k 1.0×	539 0.9×	406 1.5×	153 0.7×	354 1.7×	81	2.3k
Xiaoling Zhong China	21	798 0.8×	653 1.1×	282 1.0×	256 1.2×	156 0.8×	79	1.9k
Rossano Lattanzio Italy	29	1.3k 1.3×	959 1.6×	274 1.0×	369 1.7×	122 0.6×	83	2.7k
Oliver Renner Spain	19	1.8k 1.8×	429 0.7×	223 0.8×	174 0.8×	261 1.3×	26	3.0k
Timour Prozorovski Germany	18	1.0k 1.0×	319 0.5×	653 2.3×	286 1.4×	139 0.7×	23	2.4k
George Kulik United States	22	1.7k 1.7×	568 0.9×	220 0.8×	133 0.6×	244 1.2×	38	2.7k
Brigitte Fournier Switzerland	22	1.1k 1.2×	360 0.6×	139 0.5×	258 1.2×	268 1.3×	30	2.3k
Jilin Sun United States	16	718 0.7×	411 0.7×	297 1.1×	160 0.8×	379 1.8×	26	1.7k
Jee‐Yin Ahn South Korea	26	1.2k 1.2×	297 0.5×	309 1.1×	130 0.6×	237 1.1×	77	2.0k
Kyungmoo Yea South Korea	25	1.0k 1.0×	210 0.3×	286 1.0×	336 1.6×	116 0.6×	61	1.7k

Countries citing papers authored by Albina Nesterova

Since Specialization

Citations

This map shows the geographic impact of Albina Nesterova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albina Nesterova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albina Nesterova more than expected).

Fields of papers citing papers by Albina Nesterova

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albina Nesterova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albina Nesterova. The network helps show where Albina Nesterova may publish in the future.

Co-authorship network of co-authors of Albina Nesterova

This figure shows the co-authorship network connecting the top 25 collaborators of Albina Nesterova. A scholar is included among the top collaborators of Albina Nesterova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albina Nesterova. Albina Nesterova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Bernard A., John J. Gosink, Kelly Hensley, et al.. (2022). 1187 Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors. Regular and Young Investigator Award Abstracts. A1231–A1231. 10 indexed citations

Kulukian, Anita, Albina Nesterova, Kelly Hensley, et al.. (2020). Abstract 1962: Preclinical characterization of tucatinib in HER2-amplified xenograft and CNS implanted tumors. Cancer Research. 80(16_Supplement). 1962–1962. 2 indexed citations

Liu, Bernard A., John J. Gosink, Anthony Cao, et al.. (2020). Abstract 5581: Enfortumab vedotin, an anti-Nectin-4 ADC demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers. Cancer Research. 80(16_Supplement). 5581–5581. 24 indexed citations

Sandall, Sharsti, Marsha L. Mason, Lori Westendorf, et al.. (2019). Abstract 2688: SGN-CD228A: A novel humanized anti-CD228 antibody-drug conjugate for the treatment of solid tumors. 2688–2688. 1 indexed citations

Gordon, Kristine A., Sharsti Sandall, Jamie B. Miyamoto, et al.. (2016). Abstract 1195: SGN-CD352A: A novel humanized anti-CD352 antibody-drug conjugate for the treatment of multiple myeloma. Cancer Research. 76(14_Supplement). 1195–1195. 12 indexed citations

Sussman, Django, Leia M. Smith, Martha E. Anderson, et al.. (2014). SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer. Molecular Cancer Therapeutics. 13(12). 2991–3000. 104 indexed citations

Sandall, Sharsti, Martha E. Anderson, Mechthild Jonas, et al.. (2014). Abstract 2647: SGN-CD70A, a novel and highly potent anti-CD70 ADC, induces double-strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL). Cancer Research. 74(19_Supplement). 2647–2647. 9 indexed citations

Ryan, Maureen C., Heather Kostner, Karen A. Gordon, et al.. (2010). Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75. British Journal of Cancer. 103(5). 676–684. 68 indexed citations

Sutherland, May Kung, Changpu Yu, Timothy S. Lewis, et al.. (2009). Anti-leukemic activity of Lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. mAbs. 1(5). 481–490. 32 indexed citations

10.

Smith, Leia M., Albina Nesterova, Maureen C. Ryan, et al.. (2008). CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. British Journal of Cancer. 99(1). 100–109. 218 indexed citations

11.

Smith, Leia M., Albina Nesterova, Stephen C. Alley, Michael Torgov, & Paul J. Carter. (2006). Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Molecular Cancer Therapeutics. 5(6). 1474–1482. 76 indexed citations

12.

Law, Che‐Leung, Julie A. McEarchern, Charles G. Cerveny, et al.. (2005). The Humanized Anti-CD40 Monoclonal Antibody SGN-40 Targets Hodgkin’s Disease Cells through Multiple Mechanisms.. Blood. 106(11). 1476–1476. 5 indexed citations

13.

Pugazhenthi, Subbiah, Albina Nesterova, Purevsuren Jambal, et al.. (2003). Oxidative stress‐mediated down‐regulation of bcl‐2 promoter in hippocampal neurons. Journal of Neurochemistry. 84(5). 982–996. 98 indexed citations

14.

Jambal, Purevsuren, Albina Nesterova, Ron J. Bouchard, et al.. (2003). Cytokine-mediated Down-regulation of the Transcription Factor cAMP-response Element-binding Protein in Pancreatic β-Cells. Journal of Biological Chemistry. 278(25). 23055–23065. 64 indexed citations

15.

Watson, P.A., Charles Vinson, Albina Nesterova, & Jane E.B. Reusch. (2002). Content and Activity of cAMP Response Element-Binding Protein Regulate Platelet-Derived Growth Factor Receptor-α Content in Vascular Smooth Muscles. Endocrinology. 143(8). 2922–2929. 11 indexed citations

16.

Klemm, Dwight J., P.A. Watson, Maria G. Frid, et al.. (2001). cAMP Response Element-binding Protein Content Is a Molecular Determinant of Smooth Muscle Cell Proliferation and Migration. Journal of Biological Chemistry. 276(49). 46132–46141. 120 indexed citations

17.

Watson, P.A., Albina Nesterova, Charles Burant, Dwight J. Klemm, & Jane E.B. Reusch. (2001). Diabetes-related Changes in cAMP Response Element-binding Protein Content Enhance Smooth Muscle Cell Proliferation and Migration. Journal of Biological Chemistry. 276(49). 46142–46150. 67 indexed citations

18.

Bell, Damian C., Adrian J. Butcher, Nicholas S. Berrow, et al.. (2001). Biophysical Properties, Pharmacology, and Modulation of Human, Neuronal L-Type (α_1D, Ca_V1.3) Voltage-Dependent Calcium Currents. Journal of Neurophysiology. 85(2). 816–827. 102 indexed citations

19.

Klemm, Dwight J., J. Wayne Leitner, P.A. Watson, et al.. (2001). Insulin-induced Adipocyte Differentiation. Journal of Biological Chemistry. 276(30). 28430–28435. 160 indexed citations

20.

Pugazhenthi, Subbiah, Albina Nesterova, Carol L. Sable, et al.. (2000). Akt/Protein Kinase B Up-regulates Bcl-2 Expression through cAMP-response Element-binding Protein. Journal of Biological Chemistry. 275(15). 10761–10766. 697 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact